Accès gratuit
Biologie Aujourd'hui
Volume 208, Numéro 1, 2014
Page(s) 69 - 75
Section La vitamine D, une hormone stéroïde méconnue
Publié en ligne 23 juin 2014
  • Ali M.M., Vaidya V., Vitamin D and cancer. J Cancer Res Ther, 2007, 3, 225–230. [CrossRef] [PubMed] [Google Scholar]
  • Alroy I., Towers T.L., Freedman L.P., Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol, 1995, 15, 5789–5799. [PubMed] [Google Scholar]
  • Bianco J., Gueye Y., Marqueste T., Alluin O., Risso J.J., Garcia S., Lavault M.N., Khrestchatisky M., Féron F., Decherchi P., Vitamin D(3) improves respiratory adjustment to fatigue and H-reflex responses in paraplegic adult rats. Neuroscience, 2011, 188, 182–192. [CrossRef] [PubMed] [Google Scholar]
  • Brown J., Bianco J.I., McGrath J.J., Eyles D.W., 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett, 2003, 343, 139–143. [CrossRef] [PubMed] [Google Scholar]
  • Cantorna M.T., Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol, 2006, 92, 60–64. [CrossRef] [PubMed] [Google Scholar]
  • Cantorna M.T., Hayes C.E., DeLuca H.F., 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr, 1998a, 128, 68–72. [PubMed] [Google Scholar]
  • Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F., 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol, 1998b, 160, 5314–5319. [PubMed] [Google Scholar]
  • Chabas J.F., Alluin O., Rao G., Garcia S., Lavaut M.N., Risso J.J., Legré R., Magalon G., Khrestchatisky M., Marqueste T., Decherchi P., Féron F., Vitamin D2 potentiates axon regeneration. J Neurotrauma, 2008, 25, 1247–1256. [CrossRef] [PubMed] [Google Scholar]
  • Chabas J.F., Stephan D., Marqueste T., Garcia S., Lavaut M.N., Nguyen C., Legré R., Khrestchatisky M., Decherchi P., Féron F., Cholecalciferol (vitamin D(3)) improves myelination and recovery after nerve injury. PLoS One, 2013, 8, e65034. [CrossRef] [PubMed] [Google Scholar]
  • Chen T.C., Wang L., Whitlatch L.W., Flanagan J.N., Holick M.F., Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem, 2003, 88, 315–322. [CrossRef] [PubMed] [Google Scholar]
  • Christakos S., Raval-Pandya M., Wernyj R.P., Yang W., Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J, 1996, 316 (Pt 2), 361–371. [PubMed] [Google Scholar]
  • Cippitelli M., Santoni A., Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol, 1998, 28, 3017–3030. [CrossRef] [PubMed] [Google Scholar]
  • Cornet A., Baudet C., Neveu I., Baron-Van Evercooren A., Brachet P., Naveilhan P., 1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res, 1998, 53, 742–746. [CrossRef] [PubMed] [Google Scholar]
  • Decherchi P., Dousset E., Jammes Y., Respiratory and cardiovascular responses evoked by tibialis anterior muscle afferent fibers in rats. Exp Brain Res, 2007, 183, 299–312. [CrossRef] [PubMed] [Google Scholar]
  • Deeb K.K., Trump D.L., Johnson C.S., Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer, 2007, 7, 684–700. [CrossRef] [PubMed] [Google Scholar]
  • Eyles D., Brown J., Mackay-Sim A., McGrath J., Féron F., Vitamin D3 and brain development. Neuroscience, 2003, 118, 641–653. [CrossRef] [PubMed] [Google Scholar]
  • Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J., Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 2005, 29, 21–30. [CrossRef] [PubMed] [Google Scholar]
  • Fernandes de Abreu D.A., Eyles D., Féron F., Vitamin D, a neuro-immunomodulator: implications for brain and autoimmune diseases. Psychoneuroendocrinology, 2009, 34S: 265–277. [CrossRef] [Google Scholar]
  • Fernandes de Abreu D.A., Landel V., Féron F., Seasonal, gestational and postnatal influences on multiple sclerosis: The beneficial role of a vitamin D supplementation during early life. J Neurol Sci, 2011, 311, 64–68. [CrossRef] [PubMed] [Google Scholar]
  • Fu G.K., Lin D., Zhang M.Y., Bikle D.D., Shackleton C.H., Miller W.L., Portale A.A., Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol, 1997, 11, 1961–1970. [PubMed] [Google Scholar]
  • Garcion E., Thanh X.D., Bled F., Teissier E., Dehouck M.P., Rigault F., Brachet P., Girault A., Torpier G., Darcy F., 1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett, 1996, 216, 183–186. [CrossRef] [PubMed] [Google Scholar]
  • Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R., Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA, 2001, 98, 6800–6805. [CrossRef] [Google Scholar]
  • Hakim I., Bar-Shavit Z., Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem, 2003, 88, 986–998. [CrossRef] [PubMed] [Google Scholar]
  • Hannah S.S., Norman A.W., 1 alpha,25(OH)2 vitamin D3-regulated expression of the eukaryotic genome. Nutr Rev, 1994, 52, 376–382. [CrossRef] [PubMed] [Google Scholar]
  • Lemire J.M., Archer D.C., 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest, 1991, 87, 1103–1107. [CrossRef] [PubMed] [Google Scholar]
  • Mathieu C., Adorini L., The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med, 2002, 8, 174–179. [CrossRef] [PubMed] [Google Scholar]
  • Mathieu C., Decallonne B., van Etten E., [1,25-dihydroxyvitamin D3: the endocrine system meets the immune system]. Verh K Acad Geneeskd Belg, 2002, 64, 71-80; discussion 80–72. [PubMed] [Google Scholar]
  • Matsumoto K., Hashimoto K., Kiyoki M., Yamamoto M., Yoshikawa K., Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes. J Dermatol, 1990a, 17, 97–103. [PubMed] [Google Scholar]
  • Matsumoto K., Hashimoto K., Nishida Y., Hashiro M., Yoshikawa K., Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun, 1990b, 166, 916–923. [CrossRef] [PubMed] [Google Scholar]
  • Nagpal S., Na S., Rathnachalam R., Noncalcemic actions of vitamin D receptor ligands. Endocr Rev, 2005, 26, 662–687. [CrossRef] [PubMed] [Google Scholar]
  • Neveu I., Naveilhan P., Baudet C., Brachet P., Metsis M., 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport, 1994a, 6, 124–126. [CrossRef] [PubMed] [Google Scholar]
  • Neveu I., Naveilhan P., Jehan F., Baudet C., Wion D., De Luca H.F., Brachet P., 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res, 1994b, 24, 70–76. [CrossRef] [PubMed] [Google Scholar]
  • Omdahl J.L., Morris H.A., May B.K., Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr, 2002, 22, 139–166. [CrossRef] [PubMed] [Google Scholar]
  • Penna G., Adorini L., Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D(3). Transplant Proc, 2001, 33, 2083–2084. [CrossRef] [PubMed] [Google Scholar]
  • Taniura H., Ito M., Sanada N., Kuramoto N., Ohno Y., Nakamichi N., Yoneda Y., Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res, 2006, 83, 1179–1189. [CrossRef] [PubMed] [Google Scholar]
  • Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., Muindi J., Fakih M., Yu W.D., Johnson C.S., Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol, 2004, 89–90, 519−526. [CrossRef] [PubMed] [Google Scholar]
  • van de Kerkhof P.C., Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs. J Investig Dermatol Symp Proc, 1996, 1, 78–81. [PubMed] [Google Scholar]
  • Wang T.T., Tavera-Mendoza L.E., Laperrière D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H., Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol, 2005, 19, 2685–2695. [CrossRef] [PubMed] [Google Scholar]
  • Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., Hewison M., Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab, 2001, 86, 888–894. [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.